JPY4,407.00
1.99% day before yesterday
Tokyo, Dec 27, 07:15 am CET
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

DAIICHI SANKYO Stock price

JPY4,410.00
-232.00 5.00% 1M
-1,096.00 19.91% 6M
+538.00 13.89% YTD
+560.00 14.55% 1Y
+1,479.50 50.49% 3Y
+1,983.67 81.76% 5Y
+3,844.33 679.61% 10Y
Tokyo, Closing price Fri, Dec 27 2024
+89.00 2.06%
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

Key metrics

Market capitalization JPY8.36t
Enterprise Value JPY7.76t
P/E (TTM) P/E ratio 33.68
EV/FCF (TTM) EV/FCF 15.91
EV/Sales (TTM) EV/Sales 4.41
P/S ratio (TTM) P/S ratio 4.76
P/B ratio (TTM) P/B ratio 5.15
Dividend yield 1.36%
Last dividend (FY25) JPY60.00
Revenue growth (TTM) Revenue growth 25.84%
Revenue (TTM) Revenue JPY1.76t
EBIT (operating result TTM) EBIT JPY248.94b
Free Cash Flow (TTM) Free Cash Flow JPY487.57b
Cash position JPY707.67b
EPS (TTM) EPS JPY130.93
P/E forward 36.93
P/S forward 4.58
EV/Sales forward 4.25
Show more

Is DAIICHI SANKYO a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

DAIICHI SANKYO Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a DAIICHI SANKYO forecast:

14x Buy
88%
2x Hold
13%

Analyst Opinions

16 Analysts have issued a DAIICHI SANKYO forecast:

Buy
88%
Hold
13%

Financial data from DAIICHI SANKYO

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,758,071 1,758,071
26% 26%
100%
- Direct Costs 419,986 419,986
7% 7%
24%
1,338,085 1,338,085
33% 33%
76%
- Selling and Administrative Expenses 632,356 632,356
34% 34%
36%
- Research and Development Expense 392,404 392,404
10% 10%
22%
313,325 313,325
79% 79%
18%
- Depreciation and Amortization 64,384 64,384
3% 3%
4%
EBIT (Operating Income) EBIT 248,941 248,941
129% 129%
14%
Net Profit 250,400 250,400
69% 69%
14%

In millions JPY.

Don't miss a Thing! We will send you all news about DAIICHI SANKYO directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Sunao Manabe
Employees 18,726
Founded 2005
Website www.daiichisankyo.co.jp

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today